Omeros (NASDAQ: OMER) — Company Overview, News & Financial Data
Omeros develops small-molecule and protein therapeutics targeting immune and central nervous system diseases to address unmet needs.
Omeros
Omeros (NASDAQ:OMER) specializes in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market and orphan indications. Targeting a range of diseases including those related to the immune system, inflammation, and central nervous system, Omeros is passionately involved in advancing a diverse portfolio of promising treatment options. With a focus on addressing unmet medical needs, Omeros' operations span from research and development to marketing its approved products. The company's projects aim to harness innovative science in pursuit of breakthrough therapies, evidencing its commitment to improving patients' lives. By continuously exploring novel pathways and mechanisms, Omeros strives to expand its impact across various therapeutic areas, aiming for substantial contributions to medical care and patient well-being globally.
Snapshot
Operations
Products and/or services of Omeros
- Narsoplimab, a novel treatment targeting lectin pathway disorders, is primarily focused on hematopoietic stem cell transplant-associated thrombotic microangiopathies.
- OMS721, an investigational human monoclonal antibody targeting MASP-2, aims at treating rare autoimmune and inflammatory disorders.
- GPR174, a G protein-coupled receptor project, is exploring its potential as a novel immuno-oncology target for enhancing antitumor immunity.
- OMS906, targeting the complement system's alternative pathway, is in development for paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases.
- Omidria, a product used during cataract surgery or intraocular lens replacement, helps maintain pupil dilation and reduce postoperative ocular pain.
- OMS527, focused on addiction and compulsive disorders, is exploring the pharmacology of addiction pathways for potential new therapies.
Omeros executive team
- Gregory A. DemopulosCo-Founder, Chairman, CEO & President
- David J. BorgesVP of Finance, Chief Accounting Officer & Treasurer
- Peter B. CancelmoVP, General Counsel & Corporate Secretary
- Pamela Pierce PalmerCo-Founder
- George A. GaitanarisChief Scientific Officer & VP of Science
- Peter W. WilliamsVice President of Human Resources
- Catherine A. MelfiChief Regulatory Officer & VP of Regulatory Affairs and Quality Systems
- David W. GhesquiereVP & Chief Business Development Officer
- William E. WoodmanVP & Chief Commercial Officer
Key financials
Reported results for Omeros , in USD.
- Market cap
- 1.3B
- Revenue (TTM)
- 38.4M
- P/E ratio
- 15.0
- EPS (diluted, TTM)
- 1.2
- Dividend yield
- —
- Profit margin
- 324.9%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -122.8M | -3.4M | |
| 0 | -169.3M | -156.8M | |
| 0 | -164.5M | -117.8M | |
| 0 | -163.4M | 47.4M |